Your browser doesn't support javascript.
loading
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive).
Yong, Kwee L; Hinsley, Samantha; Auner, Holger W; Bygrave, Ceri; Kaiser, Martin F; Ramasamy, Karthik; De Tute, Ruth M; Sherratt, Debbie; Flanagan, Louise; Garg, Mamta; Hawkins, Stephen; Williams, Catherine; Cavenagh, Jamie; Rabin, Neil K; Croft, James; Morgan, Gareth; Davies, Faith; Owen, Roger G; Brown, Sarah R.
Afiliação
  • Yong KL; Cancer Institute, University College London, London. kwee.yong@ucl.ac.uk.
  • Hinsley S; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds.
  • Auner HW; Department of Immunology and Inflammation and The Hugh and Josseline Langmuir Centre for Myeloma Research, Imperial College London, London.
  • Bygrave C; Cardiff and Vale University Health Board, Cardiff.
  • Kaiser MF; The Institute of Cancer Research, London, UK and The Royal Marsden Hospital NHS Foundation Trust, London.
  • Ramasamy K; Department of Clinical Haematology, Oxford University Hospitals NHS Trust, Oxford.
  • De Tute RM; Department of Clinical Haematology, Leeds Teaching Hospitals NHS Trust, Leeds.
  • Sherratt D; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds.
  • Flanagan L; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds.
  • Garg M; Department of Haematology, University Hospitals of Leicester NHS Trust, Leicester.
  • Hawkins S; The Clatterbridge Cancer Centre, Liverpool.
  • Williams C; Centre for Clinical Haematology, Nottingham University Hospitals, Nottingham.
  • Cavenagh J; Department of Haematology, St Bartholomew's Hospital, London.
  • Rabin NK; Department of Haematology, University College Hospital, London.
  • Croft J; The Institute of Cancer Research, London, UK and The Royal Marsden Hospital NHS Foundation Trust, London.
  • Morgan G; Perlmutter Cancer Center, NYU Langone Health, New York.
  • Davies F; Perlmutter Cancer Center, NYU Langone Health, New York.
  • Owen RG; Haematological Malignancy Diagnostic Service (HMDS), St James's University Hospital, Leeds.
  • Brown SR; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds.
Haematologica ; 106(10): 2694-2706, 2021 10 01.
Article em En | MEDLINE | ID: mdl-33910333
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article